stocktitan.net

Q32 Bio Reports Q2 2026 Results and Completes Public Offering

Q32 Bio logoQ32 Bio
Sig2.70Sen+4.60Env0.00Soc0.00Gov0.00

Q32 Bio reported Q2 2026 financial results and updates, including positive 36-week topline data from Part B of its SIGNAL-AA Phase 2a trial of bempikibart in severe and very severe alopecia areata. Additional Week 36 details and initial Week 52 off-drug findings will be shared at a medical conference in H2 2026. With $106.3 million cash at June 30 and July 2026 offering proceeds, the company expects runway through Phase 3 topline results and plans regulatory discussions later in 2026 before starting a registration-directed program in 1H 2027.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro